Reproducibility of scoring criteria for HER2 immunohistochemistry in endometrial serous carcinoma: a multi-institutional interobserver agreement study-Reference-Cited by-同舟云学术

Reproducibility of scoring criteria for HER2 immunohistochemistry in endometrial serous carcinoma: a multi-institutional interobserver agreement study

Published:2021-02-03 Issue:6 Volume:34 Page:1194-1202
ISSN:0893-3952
Container-title:Modern Pathology
language:en
Short-container-title:Mod Pathol

Author:

Buza Natalia^ORCID,Euscher Elizabeth D.^ORCID,Matias-Guiu Xavier,McHenry Austin,Oliva Esther,Ordulu Zehra^ORCID,Parra-Herran Carlos^ORCID,Rottmann Douglas^ORCID,Turner Bradley M.,Wong Serena,Hui Pei^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Pathology and Forensic Medicine

Link

http://www.nature.com/articles/s41379-021-00746-5.pdf

Reference32 articles.

1. Twomey JD, Brahme NN, Zhang B. Drug-biomarker co-development in oncology - 20 years and counting. Drug Resist Updat. 2017;30:48–62.

2. Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, et al. Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2/neu. J Clin Oncol. 2018;36:2044–51.

3. Fader, AN, Roque, DM, Siegel, E, Buza, N, Hui, P, Abdelghany, O et al. Randomized phase II trial of carboplatin-paclitaxel compared with carboplatin-paclitaxel-trastuzumab in advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress Her2/Neu (NCT01367002): updated overall survival analysis. Clin Cancer Res. https://doi.org/10.1158/1078-0432.CCR-20-0953 (2020).

4. National Comprehensive Cancer Network. Uterine Neoplasms (Version 4.2019), https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf Accessed October, 2019.

5. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007;131:18–43.

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reproducibility of c-Met Immunohistochemical Scoring (Clone SP44) for Non–Small Cell Lung Cancer Using Conventional Light Microscopy and Whole Slide Imaging;American Journal of Surgical Pathology;2024-07-08

2. Human epidermal growth factor receptor-2 (HER2) expression in FIGO3 high-grade endometrial endometrioid carcinoma: Clinicopathologic characteristics and future directions;Gynecologic Oncology;2024-06

3. Implementation of HER2 Testing in Endometrial Cancer, a Summary of Real-World Initial Experience in a Large Tertiary Cancer Center;Cancers;2024-05-31

4. High-Grade Endometrial Cancer: Molecular Subtypes, Current Challenges, and Treatment Options;Reproductive Sciences;2024-04-24

5. HER2 evaluation for clinical decision making in human solid tumours: pearls and pitfalls;Histopathology;2024-03-05